---
audienceLevel: patient
cancerTypes:
- skin
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Retifanlimab-dlwr - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/retifanlimab-dlwr
version: v1
---

# Retifanlimab-dlwr - NCI

# Retifanlimab-dlwr

Placeholder slot

(REH-tih-FAN-lih-mab)

Retifanlimab-dlwr is a type of drug called an immune checkpoint inhibitor. It works by binding to the protein PD-1 on the surface of certain immune cells called T cells, which keeps cancer cells from suppressing the immune system. This allows the immune system to attack the cancer cells.

US Brand Name(s)

Zynyz

FDA Approved

Yes

[FDA label information for this drug is available at DailyMed.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=109648d0-d30a-42fc-8273-39cb1540a751&audience=consumer)

## Use in Cancer

Retifanlimab-dlwr
is approved to treat adults with:

- **[Merkel cell carcinoma](/Common/PopUps/popDefinition.aspx?id=658511&version=Patient&language=English)** (a type of [skin cancer](/Common/PopUps/popDefinition.aspx?id=445084&version=Patient&language=English)) that has spread or has come back.

Retifanlimab-dlwr is approved under FDAâ€™s Accelerated Approval Program. As a condition of approval, [confirmatory trial(s)](/Common/PopUps/popDefinition.aspx?id=799146&version=Patient&language=English) must show that it provides a clinical benefit in these patients.

Retifanlimab-dlwr
is also being studied in the treatment of other types of
cancer.

## More About Retifanlimab-dlwr

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/791453) - Detailed scientific definition and other names for this drug.

MedlinePlus Information on [Retifanlimab-dlwr](https://medlineplus.gov/druginfo/meds/a623017.html) - A lay language summary of important information about this drug that may include the following:

- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

## Research Results and Related Resources

[Targeted Cancer Therapies](https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies)

[Monoclonal Antibodies](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies)

[Immune Checkpoint Inhibitors](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/checkpoint-inhibitors)

## Clinical Trials Accepting Patients

[Find Clinical Trials for Retifanlimab-dlwr](https://www.cancer.gov/research/participate/clinical-trials/intervention/C142168) - Check for trials from NCI's list of cancer clinical trials now accepting patients.
